2021-11-05T14:07:09-05:00 2020-12-31 221430039 SOBEL & CO LLC CPA'S 293 EISENHOWER PARKWAY LIVINGSTON NJ 070391711 990 2020-01-01 208735688 SOLVING KIDS CANCER INC SOLV 2125886624 1 EAST 53RD STREET 5TH FLOOR NEW YORK NY 10022 SCOTT KENNEDY EXECUTIVE DIRECTOR 2125886624 2021-11-05 1 SCOTT KENNEDY 999009999 BRIDGET HARTNETT P01429163 9739949494 2021-11-05 2 AAL1 IAL1 2020 2022-09-23 18:48:47Z SCOTT KENNEDY 1 EAST 53RD STREET 5TH FLOOR NEW YORK NY 10022 872587 0 X WWW.SOLVINGKIDSCANCER.ORG X 2006 NY MAKE RADICAL IMPROVEMENTS IN SURVIVAL OUTCOMES FOR CHILDREN WITH THE MOST FATAL PEDIATRIC CANCERS USING A PATIENT-CENTRIC APPROACH OF DRIVING/SUPPORTING HIGH-IMPACT CLINICAL RESEARCH, PRECLINICAL THERAPEUTIC DEVELOPMENT PROJECTS, CONDUCTING RESEARCH ADVOCACY IN THE LANDSCAPE AND EMPOWERING FAMILIES WITH RESOURCES/TOOLS TO HELP THEM NAVIGATE TREATMENT OPTIONS FOR THEIR CHILD. 11 10 5 16 0 0 1166474 831151 0 0 57798 41436 263432 -21806 1487704 850781 645833 13670 0 0 408357 442390 0 32496 174163 326586 161763 1380776 650319 106928 200462 3069943 3266526 19426 15547 3050517 3250979 X SKC IMPACTS CHILDREN THROUGH THE INITIATION OF CLINICAL RESEARCH TRIALS OF INVESTIGATIONAL TREATMENT STRATEGIES. OUR VISION IS TO CONTINUE EXPANDING THE ARMAMENTARIUM OF EFFECTIVE AND LESS TOXIC TREATMENT STRATEGIES FOR PEDIATRIC ONCOLOGISTS TO UTILIZE UNTIL LONG-TERM SURVIVAL IS A REALITY FOR ALL CHILDREN WITH HIGH-RISK SOLID TUMORS AND BRAIN TUMORS.TO ACCOMPLISH OUR MISSION, SOLVING KIDS' CANCER FINDS, FUNDS AND ADVOCATES FOR BREAKTHROUGH TREATMENT OPTIONS TO CURE CHILDREN WITH THE MOST FATAL PEDIATRIC CANCERS THROUGH COLLABORATIVE PARTNERSHIPS WITH THE RESEARCH COMMUNITY AND RELATED NONPROFIT STAKEHOLDERS. 0 0 357341 13670 SKC AND ITS ADVISORS SURVEY THE PEDIATRIC CANCER LANDSCAPE TO UNDERSTAND AND PRIORITIZE THE GREATEST UNMET NEEDS OF PATIENTS AND DEVELOPS AND FUNDS PROGRAMS TO ADDRESS THEM. (1) SKC TAKES A GLOBAL APPROACH TO OUR PROGRAMS RATHER THAN LOCAL, TO LEVERAGE THE COLLECTIVE POWER OF COLLABORATION ACROSS SEVERAL CENTERS-OF-EXCELLENCE TO BREAK DOWN BARRIERS, SPEED PROGRESS AND HAVE MORE CHILDREN ACCESS PROMISING TREATMENTS. (2) PRIORITIZES AND FOCUSES ON MOST FATAL CHILDHOOD CANCER TYPES WITH <50% SURVIVAL INCLUDING HIGH RISK SOLID TUMORS AND BRAIN TUMORS. (3) DIRECTS RESEARCH FUNDING AND PROGRAMS TO THE FRONTLINES OF IMPACTING CHILDREN CLINICAL TRIALS AND DEVELOPING NEW TREATMENTS. (4) BUILD COALITIONS AND PARTNERSHIPS WITH OTHER NONPROFITS IN COLLABORATIVELY DRIVING AND FUNDING RESEARCH PROJECTS FOR GREATER IMPACT AND SCALE BECAUSE WE ARE MUCH MORE EFFECTIVE TOGETHER THAN WORKING ALONE.SURVIVAL RATES REMAIN UNSATISFACTORILY LOW FOR THE DEADLIEST CHILDHOOD CANCERS WHILE DECADES-OLD MODALITIES LIKE CHEMOTHERAPY AND RADIATION REMAIN THE PROMINENT STANDARDS-OF-CARE AND ARE NOT CURATIVE FOR NEARLY HALF OF HIGH-RISK PATIENTS. SKC FOCUSES ON ADVANCING NOVEL AGENTS/COMBINATIONS IN ALL PHASES OF THE TREATMENT SPECTRUM WITH THE HIGHEST CURATIVE RATIONALE, STARTING IN CHILDREN WITH RELAPSE/REFRACTORY DISEASE, WITH A GOAL TO MOVE INTO FRONTLINE TREATMENT REGIMENS FOR NEWLY DIAGNOSED CHILDREN ESTABLISHING A GOLD STANDARD-OF-CARE IN A PERSONALIZED APPROACH PROVIDING THE RIGHT TREATMENTS TO THE RIGHT PATIENTS.SKC PRIORITIZES THE DELIVERY OF TRANSFORMATIVE, NEXT-GENERATION CANCER THERAPIES TO THIS POPULATION THAT INCLUDES IMMUNOTHERAPY, VACCINES, CELLULAR THERAPY, SYNERGISTIC COMBINATION TREATMENTS, NEW GENOMICALLY TARGETED DRUGS, INTERVENTIONAL RADIOLOGY TECHNIQUES AND NOVEL DELIVERY MECHANISMS. OUR CRITERIA FOR IDENTIFYING AND SUPPORTING THESE NOVEL APPROACHES AIMS TO PROVIDE MORE EFFECTIVE AND LESS TOXIC TREATMENT OPTIONS THAN THE CURRENT STANDARD-OF-CARE. SKC HAS SUPPORTED 27 CLINICAL TRIALS RESULTING IN 25 NEW EXPERIMENTAL TREATMENT OPTIONS FOR CHILDREN WITH HIGH-RISK CANCERS AND 10 PRECLINICAL DEVELOPMENT PROJECTS.OUR MOST RECENT PROGRAMS INCLUDE THE DEVELOPMENT OF A NEW IMMUNOTHERAPY CONSTRUCT AGAINST A NEWLY DISCOVERED TARGET IN NEUROBLASTOMA, MEDULLOBLASTOMA AND ETMR; PROJECTS TO ADVANCE A GENOMICALLY TARGETED THERAPEUTIC AGAINST ALK AND ANOTHER TO ADVANCE A COMBINATION THERAPY AGAINSTS POLYAMINES INTO FRONTLINE TREATMENT PROTOCOLS FOR NEUROBLASTOMA; A FIRST-EVER LARGE SCALE SINGLE-CELL GENOMIC SEQUENCING OF ETMR TUMORS TO SHED UNPRECEDENTED LIGHT ON TUMOR CELLULAR ARCHITECTURE AND COMPOSITION NOT POSSIBLE BY BULK TUMOR ANALYSES ALLOWING THE IDENTIFICATION OF ALL CELL-TYPES IN PATIENT TUMORS IN AN UNBIASED FASHION; THE ESTABLISHMENT OF A NEW PLATFORM FOR TESTING A MENU OF THERAPEUTIC OPTIONS TO INFORM SUBSEQUENT TREATMENT CHILDREN WITH MEDULLOBLASTOMA USING ORGANOTYPIC SLICE CULTURES. 357341 1 1 0 0 0 0 0 0 0 0 1 0 0 0 0 1 1 0 0 0 0 0 0 1 1 0 0 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 5 0 1 5 1 0 0 0 0 0 0 0 0 0 0 0 0 X 11 10 0 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 0 NY X THE ORGANIZATION 2125886624 1 EAST 53RD STREET 5TH FLOOR NEW YORK NY 10022 JOHN LONDON CHAIRMAN, CO-FOUNDER 2.00 X X 0 0 0 SCOTT KENNEDY EXECUTIVE DIRECTOR, CO-FOU 40.00 X X 144285 0 17839 KHALIL BARRAGE DIRECTOR 2.00 X 0 0 0 HEARN JAY CHO MD DIRECTOR 2.00 X 0 0 0 CHANNING STAVE PHD SECRETARY 2.00 X X 0 0 0 MARK SAVOYE DIRECTOR 2.00 X 0 0 0 MICHAEL NIEDZIELSKI DIRECTOR 2.00 X 0 0 0 EYAL SOFFER TREASURER 2.00 X X 0 0 0 JULIA ROUX DIRECTOR 2.00 X 0 0 0 DIALA CHOUCAIR DIRECTOR 2.00 X 0 0 0 LINDY GAD DIRECTOR 2.00 X 0 0 0 144285 0 17839 1 0 1 0 0 245934 69048 516169 831151 41436 41436 0 245934 21806 -21806 -21806 850781 0 0 19630 13670 13670 162124 91844 32724 37556 235025 127640 50803 56582 17287 13067 1489 2731 27954 17982 1278 8694 3463 1926 746 791 43701 24309 9408 9984 32496 32496 26867 14833 5065 6969 157 87 34 36 2703 1503 582 618 7696 4280 1658 1758 55116 30659 11866 12591 1818 1755 30 33 1101 612 237 252 5025 2795 1082 1148 SPONSORSHIPS 5541 5541 DUES AND SUBSCRIPTIONS 4303 2394 926 983 MISCELLANEOUS 4037 2245 869 923 MEALS AND ENTERTAINMENT 235 199 18 18 650319 357341 118815 174163 77474 724201 2939869 2532412 25000 22914 6328 229552 229552 1101 0 3585 3585 3069943 3266526 19426 15547 19426 15547 X 1155669 1024399 1894848 2226580 3050517 3250979 3069943 3266526 200462 0 X X 0 1 X 1 0 X 1198351 1715498 1418138 1166474 831151 6329612 1198351 1715498 1418138 1166474 831151 6329612 573030 5756582 4821 4719 11326 57798 41436 120100 6449712 0.89250 0.91030 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 5160 5160 0 224392 224392 0 0 X 850781 0 850781 0 850781 650319 0 650319 0 650319 PART X, LINE 2: THE ORGANIZATION FOLLOWS STANDARDS THAT PROVIDE CLARIFICATION ON ACCOUNTING FOR UNCERTAINTY IN INCOME TAXES RECOGNIZED IN THE ORGANIZATION'S FINANCIAL STATEMENTS. THE GUIDANCE PRESCRIBES A RECOGNITION THRESHOLD AND MEASUREMENT ATTRIBUTE FOR THE RECOGNITION AND MEASUREMENT OF A TAX POSITION TAKEN OR EXPECTED TO BE TAKEN IN A TAX RETURN, AND ALSO PROVIDES GUIDANCE ON DERECOGNITION, CLASSIFICATION, INTEREST AND PENALTIES, DISCLOSURE AND TRANSITION. THE ORGANIZATION'S POLICY IS TO RECOGNIZE INTEREST AND PENALTIES ON UNRECOGNIZED TAX BENEFITS IN INCOME TAX EXPENSE. NO INTEREST AND PENALTIES WERE RECORDED DURING 2020 AND 2019. AT DECEMBER 31, 2020 AND 2019, THERE ARE NO SIGNIFICANT INCOME TAX UNCERTAINTIES. X X 1 STREETLIGHT DIGITAL 13396 LAFAYETTE WAY THORNTON CO 80241 CONSULT ON THE SHOELACES AND YEAR-END FUNDRAISERS 0 102933 32496 70437 102933 32496 70437 NY SPRING CELEBRATION 185307 185307 4804 SEPTEMBER CAMPAIGN 33774 33774 16187 2 26853 26853 815 245934 245934 21806 21806 -21806 1 BOSTON CHILDREN'S HOSPITAL 401 PARK DRIVE SUITE 602 BOSTON MA 02215 042774441 501(C)(3) 21244 CASH CANCER RESEARCH UNIVERSITY OF MINNESOTA 450 MCNAMARA ALUMNI CENTER 200 OAK STREET MINNEAPOLIS MN 55455 416007513 501(C)(3) -7574 CASH REFUND CANCER RESEARCH - RETURN OF UNUSED FUNDS PART I, LINE 2: THE ORGANIZATION EXPENDS FUNDS IN CONNECTION WITH GRANT COMMITMENTS AS EACH GRANTEE ACCOMPLISHES SPECIFIC MILESTONES SET FORTH IN EACH GRANT AGREEMENT. EACH GRANTEE IS REQUIRED TO SUBMIT PROGRESS REPORTS ON A PERIODIC BASIS AS MILESTONES ARE ACHIEVED PURSUANT TO THE GRANT AGREEMENTS. IF FUNDS ARE NOT USED BY THE GRANTEE IN ACCORDANCE WITH THE AGREEMENT, FUNDS ARE RETURNED. X X X 0 0 0 0 0 0 0 0 0 SCOTT KENNEDY EXECUTIVE DIRECTOR, CO-FOU 144285 0 0 0 0 0 0 0 17839 0 162124 0 0 0 PART I, LINE 3 FAIR MARKET VALUE COMPARISON OF SIMILAR ORGANIZATIONS FORM 990, PART VI, SECTION B, LINE 11B THE COMPLETED FORM 990 IS SENT TO THE BOARD OF DIRECTORS PRIOR TO FILING FOR REVIEW AND APPROVAL. FORM 990, PART VI, SECTION B, LINE 12C THE ORGANIZATION DISTRIBUTES A CONFLICT OF INTEREST POLICY TO EACH BOARD MEMBER ANNUALLY AT THE BOARD MEETING. ALL STAFF AND BOARD MEMBERS ARE REQUIRED TO SIGN A CONFLICT OF INTEREST POLICY STATEMENT ON AN ANNUAL BASIS. ANY CONFLICTS THAT ARISE DURING THE COURSE OF THE YEAR ARE REQUIRED TO BE DISCLOSED AND RESOLVED BEFORE THE TRANSACTION IS COMPLETED. FORM 990, PART VI, SECTION B, LINE 15 COMPENSATION IS DETERMINED BY CONDUCTING A FAIR MARKET VALUE COMPARISON OF OTHER ORGANIZATIONS BY THE BOARD CHAIR. FACTORS INCLUDE THE NUMBER OF HOURS WORKED AND THE BREADTH OF ROLES AND RESPONSIBILITIES. FORM 990, PART VI, SECTION C, LINE 18 THE ORGANIZATION'S FORM 990 IS AVAILABLE UPON REQUEST. FORM 990, PART VI, SECTION C, LINE 19 THE ORGANIZATION'S GOVERNING DOCUMENTS IS MADE AVAILABLE UPON REQUEST. FORM 990, PART XII, LINE 2C: THE BOARD OF DIRECTORS IS CHARGED WITH OVERSIGHT IN REGARDS TO REVIEW OF THE FINANCIALS AND SELECTION OF THE AUDITOR. THE OVERSIGHT PROCESS HAS NOT CHANGED FROM THE PRIOR YEAR.